Nrf2 activation inhibits valproic acid-induced neural tube defects in mice

2021 ◽  
pp. 107039
Author(s):  
Ted B. Piorczynski ◽  
Samantha Lapehn ◽  
Kelsey P. Ringer ◽  
Spencer A. Allen ◽  
Garett A. Johnson ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Neural Tube ◽  
Neural Tube Defects ◽  
Nrf2 Activation

Trimethoprim potentiates valproic acid-induced Neural Tube Defects (NTDs) in mice

1993 ◽  
Vol 7 (3) ◽  
pp. 249-254 ◽  
Author(s):  
Mohamed M.A. Elmazar ◽  
Heinz Nau
Keyword(s):  
Valproic Acid ◽  
Neural Tube ◽  
Neural Tube Defects

Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite

Teratology ◽  
1988 ◽  
Vol 38 (4) ◽  
pp. 313-320 ◽  
Author(s):  
Richard H. Finnell ◽  
Gregory D. Bennett ◽  
Steven B. Karras ◽  
Virginia K. Mohl
Keyword(s):  
Valproic Acid ◽  
Neural Tube ◽  
Neural Tube Defects ◽  
Mouse Embryos ◽  
Acid Metabolite

Inhibition of valproic acid-induced neural tube defects through Nrf2 signaling

2017 ◽  
Vol 112 ◽  
pp. 193
Author(s):  
Ted B. Piorczynski ◽  
S. Marc Lucas ◽  
Britney K. Oxley ◽  
Jason M. Hansen
Keyword(s):  
Valproic Acid ◽  
Neural Tube ◽  
Neural Tube Defects

scholarly journals Valproic Acid–Induced Deregulation In Vitro of Genes Associated In Vivo with Neural Tube Defects

2009 ◽  
Vol 108 (1) ◽  
pp. 132-148 ◽  
Author(s):  
Måns Jergil ◽  
Kim Kultima ◽  
Anne-Lee Gustafson ◽  
Lennart Dencker ◽  
Michael Stigson
Keyword(s):  
Valproic Acid ◽  
Neural Tube ◽  
Neural Tube Defects

Valproate Teratogenicity

PEDIATRICS ◽  
1983 ◽  
Vol 71 (6) ◽  
pp. 980-980
Author(s):  
Keyword(s):  
Valproic Acid ◽  
Disease Control ◽  
Neural Tube ◽  
Neural Tube Defects ◽  
Prenatal Testing ◽  
First Trimester ◽  
Teratogenic Effects ◽  
Recent Statement ◽  
Estimated Risk ◽  
First Trimester Of Pregnancy

In a recent statement entitled, "Valproic Acid: Benefits and Risks" we reported that despite the presence of teratogenic effects in animals there existed only one possible case in man.1 Recently the Centers for Disease Control has reported that the use of valproic acid (Depakene), during the first trimester of pregnancy, may increase the risk of having a child with spina bifids.2 The report, based upon a study undertaken in Rhône-Alpes, France,3,4 quotes an estimated risk of 1.2%. Based upon this information, we believe that a woman who becomes pregnant while on valproic acid should consult with her physician about prenatal testing for neural tube defects. Additional recommendations for the counseling of women who require anticounvulsant treatment during pregnancy have been published previously.5

Sign in / Sign up

Export Citation Format

Share Document